## REMARKS

Upon entry of the foregoing amendments, claims 10-12 and 25 are under consideration and pending in the application.

In response to the August 13, 2003 Restriction Requirement, Applicants elect without traverse Group II directed to polypeptides and elect SEQ ID NO: 4. Applicants make this election without prejudice to pursuing non-elected subject matter in later applications. Support for the amendments to claims 10 and 12 are found in the specification at least in the originally filed claims 10 and 12, respectively. In addition, no change in inventorship under 37 C.F.R. §1.48(b) is merited by electing Group II under 37 C.F.R. §1.121 and as such, no request under 37 C.F.R. §1.48(b) or fee under 37 C.F.R. §1.17(i) are submitted.

## CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance, and a Notice of Allowance is respectfully requested as soon as possible. If there are any questions regarding these amendments and remarks, or if further discussion would expedite allowance of the claims, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Date: August 28, 2003

Renée S. Polizotto, Ph.D.

Agent for Applicants
Registration No.: 53,474

Customer No. 34285

NUVELO, Inc.

675 Almanor Avenue Sunnyvale, CA 94085

Tel.: 408.215.4000 Fax: 408.524.8145

U.S. Serial No. 09/756,247